Literature DB >> 17998938

Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas.

A Colomba1, D Courilleau, D Ramel, D D Billadeau, E Espinos, G Delsol, B Payrastre, F Gaits-Iacovoni.   

Abstract

The majority of anaplastic large cell lymphomas (ALCLs) express the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) fusion protein, which is oncogenic due to its constitutive tyrosine kinase activity. Transformation by NPM-ALK not only increases proliferation, but also modifies cell shape and motility in both lymphoid and fibroblastic cells. We report that the Rac1 GTPase, a known cytoskeletal regulator, is activated by NPM-ALK in ALCL cell lines (Karpas 299 and Cost) and transfected cells (lymphoid Ba/F3 cells, NIH-3T3 fibroblasts). We have identified Vav3 as one of the exchange factors involved in Rac1 activation. Stimulation of Vav3 and Rac1 by NPM-ALK is under the control of Src kinases. It involves formation of a signaling complex between NPM-ALK, pp60(c-src), Lyn and Vav3, in which Vav3 associates with tyrosine 343 of NPM-ALK via its SH2 domain. Moreover, Vav3 is phosphorylated in NPM-ALK positive biopsies from patients suffering from ALCL, demonstrating the pathological relevance of this observation. The use of Vav3-specific shRNA and a dominant negative Rac1 mutant demonstrates the central role of GTPases in NPM-ALK elicited motility and invasion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17998938     DOI: 10.1038/sj.onc.1210921

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

1.  β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Authors:  Mona Anand; Raymond Lai; Pascal Gelebart
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

2.  Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor.

Authors:  Bin Shi; Deeksha Vishwamitra; J Gabrielle Granda; Thomas Whitton; Ping Shi; Hesham M Amin
Journal:  Neoplasia       Date:  2013-06       Impact factor: 5.715

3.  Genetic alterations affecting GTPases and T-cell receptor signaling in peripheral T-cell lymphomas.

Authors:  Rebecca L Boddicker; Gina L Razidlo; Andrew L Feldman
Journal:  Small GTPases       Date:  2017-01-06

4.  Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.

Authors:  Fang Wu; Peng Wang; Jingdong Zhang; Leah C Young; Raymond Lai; Liang Li
Journal:  Mol Cell Proteomics       Date:  2010-04-14       Impact factor: 5.911

5.  NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation.

Authors:  E E Bosco; Y Nakai; R F Hennigan; N Ratner; Y Zheng
Journal:  Oncogene       Date:  2010-02-15       Impact factor: 9.867

6.  Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models.

Authors:  Rute B Marques; Natasja F Dits; Sigrun Erkens-Schulze; Wytske M van Weerden; Guido Jenster
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

7.  NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.

Authors:  Chiara Ambrogio; Cinzia Martinengo; Claudia Voena; Fabrizio Tondat; Ludovica Riera; Paola Francia di Celle; Giorgio Inghirami; Roberto Chiarle
Journal:  Cancer Res       Date:  2009-11-03       Impact factor: 12.701

Review 8.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

9.  Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.

Authors:  Fayi Wu; Stephanie O Peacock; Shuyun Rao; Sandra K Lemmon; Kerry L Burnstein
Journal:  J Biol Chem       Date:  2012-12-31       Impact factor: 5.157

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.